Tuesday, November 15, 2011

Clot Wars contd. - Doctors reserve judgment on new blood clot drugs | Reuters

Investors have tried to bet on which of the three will become the dominant player in a race between Xarelto from Bayer and Johnson & Johnson, apixaban by Pfizer Inc and Bristol-Myers Squibb, and Boehringer Ingelheim's Pradaxa.

Many cardiologists at the American Heart Association meeting this week said they were reserving judgment about whether any one drug is better for their patients. Some said safety concerns and cost could outweigh their benefits.

"I'm more confused than informed," Dr Sanjay Kaul, a prominent heart doctor at Cedars-Sinai in Los Angeles, said after hearing presentations on the medicines at the meeting in Orlando.

"The anti-thrombotic landscape has become more fuzzy for me, and it will continue to be fuzzy for the next few years until we make some sense out of the data."

Posted via email from Jack's posterous

No comments: